Myriad Geneticsの空売り状況は、投資家がMyriad Geneticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Myriad Genetics (NASDAQ:MYGN) 株価情報, 空売り情報

Myriad Genetics

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Myriad Genetics Inc

WIIM

MYGN

Myriad Genetics shares are trading higher on possible continued strength after Craig-Hallum initiated coverage on the stock yesterday with a Buy rating and announced a price target of $29.

Throughout the last three months, 8 analysts have evaluated Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Myriad Genetics and provided 12-month price targets. The average target is $19.25, accompanied by a high estimate of $29.00 and a low estimate of $13.00. Observing a downward trend, the current average is 23.0% lower than the prior average price target of $25.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1739383256_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Myriad Genetics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Wilkin</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$29.00</td>
<td>-</td>
</tr>
<tr>
<td>John Peterson</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$21.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Myriad Genetics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Myriad Genetics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Myriad Genetics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Myriad Genetics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Myriad Genetics's Background</h2>
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
<h3>Breaking Down Myriad Genetics's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Myriad Genetics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 11.15%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Myriad Genetics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -10.36% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -3.0%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Myriad Genetics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -2.04%, the company showcases efficient use of assets and strong financial health.
Debt Management: Myriad Genetics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.2.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Expert Outlook: Myriad Genetics Through The Eyes Of 8 Analysts

Craig-Hallum analyst John Wilkin initiates coverage on Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Buy rating and announces Price Target of $29.

News

Price Target

Initiation

Craig-Hallum Initiates Coverage On Myriad Genetics with Buy Rating, Announces Price Target of $29

<a href="https://www.globenewswire.com/Tracker?data=SIENRpnqwt49I6MvTNNvksHftlhZmNcpestMkJhoe4w_gmoJvO3me5xwmQ5Z-12BroOwgxACTPneBQX8lN7ibw==">Myriad Genetics, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced an agreement designed to enhance education and access to hereditary cancer testing for <a href="https://www.globenewswire.com/Tracker?data=KYqIsSBBzfJy2wEWsTes7WkzvD9tGqN-OAIOv-UuKXo69V__yDPYAMhlgBQ5E4qzjqODEMeg2xBd4b95FMNzaT1V66AkWVpC2Q4wB4b_p1g=">CancerCARE for Life</a> members.
The agreement enables more than one million individuals within CancerCARE's network to assess their eligibility for the MyRisk test by taking the <a href="https://www.globenewswire.com/Tracker?data=bcub9ByLouKCScEGr2VVSrWLzYwsW0dKR44eRm1dGi8IQmviVRNYSnVZOwZViCH6wHiBbOoalG-OTyZJWqG9BvTIkod7I2nbyy3mpnf9XzQ=">MyGeneHistory</a><a href="https://www.globenewswire.com/Tracker?data=LIm4A7Ijxb5TrFJzK0FabYexu8rCDEcSPd7ogqC6hwdKLYQVlB44izOMXJ4U_MR9g2TspQSpXbPu7NXe4R7WBg==">&#xAE;</a> quiz, a guideline-based online patient screening tool. If they meet criteria, they can be directed to a clinician who can order the <a href="https://www.globenewswire.com/Tracker?data=FIluWB4m0ZdLhrwoSWnhVnGYJ4khDHYx12CejGLyPZHb54kslLiTrG49xX2Fuj6KG8Dle7L8GWsbmERcVlsIb1pZgJ9DhyfC8EUZkgAyslfUCPcHviA9uO4U2kqrEvn_aLYwwSn8nOmoZwEZ0TitNw==">MyRisk</a><a href="https://www.globenewswire.com/Tracker?data=XMN3s6fZo1Cafdxe9lO9q9Zo3Ln16koqKuJKcW4BHzOixYK6XwsF-sMKgN4dTkl4N6B8LBUlRu9pY797HmF7Y4UKdKZmL7w0a6EUzuP9jYORTR5LeRxbvmLN6pc6uZLs">&#xAE;</a><a href="https://www.globenewswire.com/Tracker?data=eFN0OJlI3Pq9oekhA5DfD7MU6HGq_hZENWqKr3yQo_0NnKn0_FSylStZmEqsDPltxr7Hgo1guvAF5DHVGvgZr1WnbXDL6vkIVV-JMGg9nHSm4M2PsfELlG5JAwmVmq4t26__eQ5Pdgl3PvjWqoR1HA=="> with RiskScore</a><a href="https://www.globenewswire.com/Tracker?data=bdhuJZFhUW8oMK7oipcj4liaH6FbImcXhZIAoZZHlOM80bAwz735BWb3GiwjCzg2oDqZkAwPJujQ5wi_94kS1Xpwfw7Y1iT67rRiHvKZV-3b_56HeqExigY0mevMwOnZ">&#xAE;</a><a href="https://www.globenewswire.com/Tracker?data=1YVRWP_pAuDojvUHngB4CIYNC2Jf-2KYt6_LwcKJukg7VPbrqDep6AdeXYzEiTdwOY4YRfzzklj3_xlz8drXzHC0a8q9UAgwBpBxDcM5IUO7ObrF3ZNakzwZSFssYSQBtgxE0SHy8-OaHaiqNuhSoFBBIE16g-bBrcuvCQG4TrQ="> Hereditary Cancer Test</a> on their behalf. Patients who take the MyRisk test can then review their results with a Myriad genetic counselor.

Biotech

General

Myriad Genetics And INTERLINK Announce Agreement To Expand Access To Hereditary Cancer Testing For 1M CancerCARE Members Through MyRisk Test And MyGeneHistory Quiz

Myriad Genetics Announces Issuance Of Two New Patents Advancing Tumor-Genomic Testing Capabilities For MRD Assay

Piper Sandler analyst John Peterson maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Neutral and lowers the price target from $24 to $14.

Piper Sandler Maintains Neutral on Myriad Genetics, Lowers Price Target to $14

<a href="https://www.globenewswire.com/Tracker?data=Yp5pZUGkmgWeCrtxie73Rg99tLVrq9zyIeAPwL55Zi3zAnZ1OcdzY0RrblSyNb0MPiR5A57Q1ZuOsHRgoii9dA==">Myriad Genetics, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at the annual Society for Maternal-Fetal Medicine Conference (SMFM). The company's "Fetal fraction amplification enables accurate prenatal cell-free DNA (cfDNA) screening at eight weeks gestation" study was awarded SMFM's "Dru Carlson Memorial Award for Best Research in Ultrasound and Genetics."
The study found that <a href="https://www.globenewswire.com/Tracker?data=Zw1Txz9m0LZemotcUmoj_v4kBiRmqbB-RUXGk-7uly0p0sSWGcfafv_HzLGf5EPEIJIlrTR9pV_bbG9z2q2U9PGDHRnDbSZWSwBJ-VPXi34Vb6Rp0eReke0e1LV0ES-BvwDbTaVymgloiRfAhMMeI0SpUcs8LyyvgkqsUc_DEWwSrA58u3lNpgeV5zyiKwUl">Prequel&#xAE;&nbsp;Prenatal Screen with AMPLIFY&#x2122;&nbsp;technology</a> enables reliable results as early as eight-weeks' gestation. Typically, prenatal cell-free DNA (pcfDNA) screening is offered beginning at nine to 10 weeks' gestation. At earlier gestational ages, the proportion of placental cfDNA, referred to as the fetal fraction (FF), is often too low to allow for confident analysis. Prequel with AMPLIFY can overcome this limitation by increasing the FF. This study found that by using Prequel with AMPLIFY, the average FF was 12.5%, with a no-call rate of less than 0.5% between eight and 10 weeks of gestation.

Myriad Genetics Announces Prenatal DNA Screening Research; Prequel With AMPLIFY Enables Reliable Results At 8 Weeks Gestation With 12.5% Fetal Fraction And Less Than 0.5% No-Call Rate

Goldman Sachs analyst Matthew Sykes maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Buy and lowers the price target from $29 to $18.

Goldman Sachs Maintains Buy on Myriad Genetics, Lowers Price Target to $18

Myriad Genetics Announces Publication Of Hereditary Cancer Risk Assessment Program Study In Obstetrics & Gynecology

In the preceding three months, 6 analysts have released ratings for Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Myriad Genetics, presenting an average target of $19.5, a high estimate of $24.00, and a low estimate of $13.00. This current average represents a 23.23% decrease from the previous average price target of $25.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1737061230_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Myriad Genetics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$21.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>John Peterson</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Myriad Genetics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Myriad Genetics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Myriad Genetics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Myriad Genetics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Myriad Genetics: A Closer Look</h2>
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
<h3>Myriad Genetics: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Myriad Genetics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.15% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -10.36%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Myriad Genetics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.0%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Myriad Genetics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -2.04%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 0.2, Myriad Genetics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Myriad Genetics: Insights From 6 Analyst Reviews

Stephens &amp; Co. analyst Mason Carrico reiterates Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Equal-Weight and maintains $20 price target.

Reiteration

Stephens & Co. Reiterates Equal-Weight on Myriad Genetics, Maintains $20 Price Target

Guidance

Myriad Genetics Sees FY25 Adj. EPS $0.07-$0.11 Vs $0.08 Est.; Revenue $840M-$860M Vs $876.702M Est.

Myriad Genetics Sees Prelim. Q4 Adj. EPS $0.03-$0.04 Vs $0.03 Est.; Revenue $209M-$211M Vs $212.873M Est.

Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program featuring the <a href="https://www.globenewswire.com/Tracker?data=e3VsfxUbo-yZkKbrkPomsnLaoTxIULLUg8SGhzOUD3LZsVTnph0ap0ONCJT2yjG7Ru0ZDySSBGuiWyqIAOc679R1p4wjBMWp_qS-Qp2fX0WOqAyNh_GjNdsmfUCND9P7KafrTRXVKCgUhT3KL4uAZSO2gzMV4eblYoFnZYFyHHH79mO2VhGLi_cscUCakM-H">MyRisk&#xAE; with RiskScore&#xAE; Hereditary Cancer Test</a>, the first and industry-leading hereditary cancer test and polygenic risk prediction test for all ancestries. She will promote the importance of collecting a detailed family health history for cancer and understanding the associated cancer risks.
 &nbsp;

Reported Earlier, Myriad Genetics Signs Agreement With Hannah Storm To Highlight Importance Of Knowing Family Cancer Risk

The University of Texas MD Anderson Cancer Center and <a href="https://www.globenewswire.com/Tracker?data=uO4LOlwHxRiA3mIMJWKatVr7_GxQ0-d6AnrfabhLUKvu7R3iBIL8bfDg5fkj__RbKKRZMXEHird6NEZ9zn4OT7F8jil8dFHi13ElO6qS-aYF57bEtefPzhtmfZsb5fOchjaXm8cJF__sGeNiRTrAviJOC9slJu8FvlEkPjkKAGQ3A6vV1BMwR0eRn3gBraW53iQ2G68NGkKwu8hB-Ot-8eAuEl-NDJkKpyhrnIGBLLIrYaW3NeVAiJ0fD-adKku_fmadT6XWWmK0Zl7M3v63jx8NaA674H7P5ZjJdREVeDJMpHt5zNfHJ4nSvQG7zzF2iDw3dJiTSU5ma5qEXnkeblE6Idao_-NOg-G8BU3QosujovYtAsOUBfl3jwVW8GJ7">Myriad Genetics, Inc</a><a href="https://www.globenewswire.com/Tracker?data=ktTiZ9Tjy05IzKzxsQfwBlVlk_QPFq25H79djQExaqEL79wloeNCiyz-cOqVoz1vx1WJtIgyd9kvjw4io0DCIBhhkejIqRASZdZFVFwOQbP4RYzwuq1474t9SWtpCX1FVsP3MOwTB3HP65-3n0biZ0Kob3pAPuvkF93lq5MRSnst-sE4VaEnkYXr3OYHCU6SqBny9PpRvilrkoxg7vMd_sfRk7cU_V6NPigYaEa96Nqq22i9drKiogA43Brzj_rcnfL7N9Qw6xwTNiN-G6BDQN8nDlgqx9h0nyVQ3hVl3XyJYA9e7NlSClDO_ooFG4tigVXPgQaW03v-7bkj8ApvbCPn7yUNl7KA6zUVeG37u5c=">.</a> today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad's molecular residual disease (MRD) assay.
This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research expertise of MD Anderson to create a portfolio of studies to evaluate the clinical validity and utility of Myriad's Precise MRD.

The University Of Texas MD Anderson Cancer Center And Myriad Genetics Announce A 5-Year Strategic Alliance To Accelerate The Clinical Evaluation And Development Of Myriad's Molecular Residual Disease Assay

B of A Securities analyst Derik De Bruin maintains Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Underperform and lowers the price target from $15 to $13.

B of A Securities Maintains Underperform on Myriad Genetics, Lowers Price Target to $13

Reported Earlier, Myriad Genetics Engages Unitedhealthcare On Pharmacogenetic Testing Policy, Seeks Continued Access To Genesight In 2025

UBS analyst Lu Li initiates coverage on Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) with a Neutral rating and announces Price Target of $18.

UBS Initiates Coverage On Myriad Genetics with Neutral Rating, Announces Price Target of $18

In the preceding three months, 4 analysts have released ratings for Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Myriad Genetics, revealing an average target of $24.5, a high estimate of $32.00, and a low estimate of $21.00. Highlighting a 20.12% decrease, the current average has fallen from the previous average price target of $30.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1733756610_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Myriad Genetics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$21.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>John Peterson</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$32.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Myriad Genetics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Myriad Genetics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Myriad Genetics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Myriad Genetics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MYGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Myriad Genetics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Myriad Genetics</h2>
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
<h3>Myriad Genetics: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Myriad Genetics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.15% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Myriad Genetics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -10.36% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Myriad Genetics's ROE stands out, surpassing industry averages. With an impressive ROE of -3.0%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Myriad Genetics's ROA stands out, surpassing industry averages. With an impressive ROA of -2.04%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.2, Myriad Genetics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley analyst Betsy Graseck downgraded the rating for Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) from Overweight to Equal-Weight but raised the price target from $48 to $55. Bank of America shares closed at $46.75 on Friday. See how other analysts view this stock.</li>
<li>Leerink Partners analyst Puneet Souda downgraded Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) from Outperform to Market Perform and slashed the price target from $30 to $21. Myriad Genetics shares closed at $15.13 on Friday. <a href="https://www.benzinga.com/quote/MYGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Michael Yee downgraded the rating for Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) from Buy to Hold and lowered the price target from $250 to $180. Biogen shares closed at $157.78 on Friday. See how other analysts view this stock.</li>
<li>B of A Securities analyst Vivek Arya downgraded Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) from Buy to Neutral and lowered the price target from $180 to $155. AMD shares closed at $138.59 on Friday. <a href="https://www.benzinga.com/quote/AMD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Sandeep Deshpande downgraded the rating for STMicroelectronics N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) from Overweight to Neutral. STMicroelectronics shares closed at $26.43 on Friday. <a href="https://www.benzinga.com/quote/STM/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AMD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="616" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09082137/image-64-1024x616.png" alt="" class="wp-image-683191" style="width:572px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09082137/image-64-1024x616.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09082137/image-64-300x180.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09082137/image-64-768x462.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09082137/image-64.png 1093w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42380712/how-to-earn-500-a-month-from-oracle-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Oracle Stock Ahead Of Q2 Earnings</a></li>
</ul>

Downgrades

Pre-Market Outlook

Markets

Trading Ideas

BIIB

This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Myriad Genetics: Navigating Through A Setback

Myriad Genetics (MYGN) announced a study revealing that more patients completed hereditary cancer testing when they used an online screening tool a...

Myriad Genetics announces hereditary cancer risk assessment study published

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a pri...

Leerink Partners Sticks to Their Hold Rating for Myriad Genetics (MYGN)

Myriad Genetics (MYGN) has launched a new educational website providing comprehensive information about reproductive and prenatal genetic testing. ...

Myriad Genetics introduces online prenatal genetic testing resource

Myriad Genetics (MYGN) announced it will unveil groundbreaking research at the annual Society for Maternal-Fetal Medicine, SMFM, conference. The co...

Myriad Genetics unveils resesrch at SMFM on cfDNA

Myriad Genetics (MYGN) and Lumea have signed an agreement to integrate Myriad's advanced molecular diagnostic tests – Prolaris Prostate Cancer Test...

Myriad Genetics announce collab with Lumea

Myriad Genetics (MYGN) announced that the United States Patent and Trademark Office has issued two new patents that further advance Myriad's abilit...

Myriad Genetics issued two new patents from USPTO

Group meeting and tour of company headquarters with CEO Diaz, COO Raha and CFO Leffler in Salt Lake City, Utah on February 10 hosted by BTIG. Publi...

Myriad Genetics management to meet with BTIG

Craig-Hallum initiated coverage of Myriad Genetics (MYGN) with a Buy rating and $29 price target Published first on TheFly – the ultimate source fo...

Myriad Genetics initiated with a Buy at Craig-Hallum

As previously reported, Craig-Hallum initiated coverage of Myriad Genetics (MYGN) with a Buy rating and $29 price target. The firm believes the sto...

Craig-Hallum bulish on Myriad Genetics, initiates with a Buy

Press Releases

Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance

Diligent Announces Market Insights Reporting Powered by S&P Global Market Intelligence, Giving Directors and Executives Unrivaled Financial and Risk Insights

Comments

Myriad Genetics

空売り

Myriad Genetics (NASDAQ:MYGN) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル